Dennis Suskind - CME Independent Director

CME Stock  USD 215.29  0.31  0.14%   

Director

Mr. Dennis A. Suskind is an Independent Director of the Company since 2008.
Age 75
Tenure 16 years
Address 20 South Wacker Drive, Chicago, IL, United States, 60606
Phone312 930 1000
Webhttps://www.cmegroup.com

Latest Insider Transactions

2023-11-06Disposed of 1500 shares @ 213.6View
Suskind is a retired General Partner of Goldman Sachs & Co. During his tenure in trading, Mr. Suskind served as Vice Chairman of NYMEX, Vice Chairman of COMEX, a member of the board of the Futures Industry Association, a member of the board of International Precious Metals Institute, a member of the boards of the Gold and Silver Institutes in Washington, DC and was an inaugural member of the Future Industry Association’s Hall of Fame. He is the President of the board of the Hampton Classic Horse Show and of the board of the Stein Eriksen Lodge Hotel. He previously served as the President of the Arthur Ashe Institute for Urban Health for fifteen years. He also served on the board of NYMEX Holdings, Inc. until our merger in 2008.

CME Management Efficiency

The company has Return on Asset of 0.0142 % which means that on every $100 spent on assets, it made $0.0142 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1203 %, implying that it generated $0.1203 on every 100 dollars invested. CME's management efficiency ratios could be used to measure how well CME manages its routine affairs as well as how well it operates its assets and liabilities. At present, CME's Return On Assets are projected to increase slightly based on the last few years of reporting. At present, CME's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 99.6 B, whereas Other Assets are forecasted to decline to about 127.7 M.
The company has 3.88 B in debt with debt to equity (D/E) ratio of 0.12, which may show that the company is not taking advantage of profits from borrowing. CME Group has a current ratio of 1.0, demonstrating that it is in a questionable position to pay out its financial commitments when the payables are due. Debt can assist CME until it has trouble settling it off, either with new capital or with free cash flow. So, CME's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CME Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CME to invest in growth at high rates of return. When we think about CME's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Valerie PechonCorporacion America Airports
44
Erwan FaiveleyWestinghouse Air Brake
40
Andres AlonsoScholastic
60
Andrew HeddenScholastic
83
Gary ValadeWestinghouse Air Brake
72
Lee BanksWestinghouse Air Brake
58
David YoungScholastic
66
Robert BrooksWestinghouse Air Brake
73
Peter WarwickScholastic
72
Carlo MontagnaCorporacion America Airports
56
Linda HartyWestinghouse Air Brake
60
Marianne CaponnettoScholastic
65
Nickolas SteegWestinghouse Air Brake
74
Daniel MarxCorporacion America Airports
67
Philippe AlfroidWestinghouse Air Brake
73
Byron FosterWestinghouse Air Brake
52
James BargeScholastic
62
John DaviesScholastic
67
Margaret WilliamsScholastic
62
Roderick McGeochCorporacion America Airports
67
David ArendtCorporacion America Airports
67
CME Group Inc., together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. CME Group Inc. was founded in 1898 and is headquartered in Chicago, Illinois. CME operates under Financial Data Stock Exchanges classification in the United States and is traded on NASDAQ Exchange. It employs 3480 people. CME Group (CME) is traded on NASDAQ Exchange in USA. It is located in 20 South Wacker Drive, Chicago, IL, United States, 60606 and employs 3,565 people. CME is listed under Financial Exchanges & Data category by Fama And French industry classification.

Management Performance

CME Group Leadership Team

Elected by the shareholders, the CME's board of directors comprises two types of representatives: CME inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CME. The board's role is to monitor CME's management team and ensure that shareholders' interests are well served. CME's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CME's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ana Dutra, Independent Director
Daniel Glickman, Independent Director
Howard Siegel, Independent Director
Kathleen Cronin, Senior Managing Director, General Counsel, Corporate Secretary
Dennis Chookaszian, Independent Director
Kendal Vroman, Chief Officer
Michel Everaert, MD EMEA
Steven Wollack, Independent Director
William Miller, Independent Director
Derek Sammann, Senior Managing Director - Financial Products and Services
Cees Vermaas, Managing Director & CEO of CME Europe Limited
Gedon Hertshten, Independent Director
Sean Keating, MD Office
Elizabeth Cook, Independent Trustee
Daniel Kaye, Director
Douglas Monieson, Independent Director
William Knottenbelt, Senior Managing Director, Europe, Middle East, Africa (EMEA)
John Pietrowhicz, Senior Managing Director - Business Development and Corporate Finance
Jeffrey Bernacchi, Independent Director
James Oliff, Independent Director
Sunil Cutinho, President - CME Clearing
Julie Holzrichter, COO and Sr. Managing Director
Timothy Bitsberger, Independent Director
Bryan Durkin, Chief Commercial Officer and Sr. Managing Director
Patrick Maloney, Independent Director
Dennis Suskind, Independent Director
Alex Pollock, Lead Independent Director
Leo Melamed, Chairman Emeritus
Charles Carey, Vice Chairman of the Board
Hilda Piell, Chief Human Resource Officer, Senior Managing Director
Kimberly Taylor, President of Global Operations, Technology and Risk
David Wescott, Independent Director
Anita Liskey, Senior Communications
Edemir Pinto, Independent Director
Deborah Lucas, Independent Director
John Sandner, Director
Jack Tobin, Chief Accounting Officer, Managing Director
Larry Gerdes, Independent Director
Phupinder Gill, CEO, Director, Member of Competitive Markets Advisory Council, Member of Executive Committee and Member of Strategic Steering Committee
Linda Rich, Senior Managing Director - Government Relations and Legislative Affairs
Terry Savage, Independent Director
Bruce Johnson, Independent Director
Jonathan Marcus, Senior Counsel
Julie Winkler, Senior Managing Director - Research and Product Development
Ronald Pankau, Independent Director
Kevin Kometer, CIO, Senior Managing Director
Robert Zagotta, Senior Managing Director - Products and Services
Lynne Fitzpatrick, Chief Officer
Yra Harris, Director
Jill Harley, Managing Director
Terrence Duffy, Executive Chairman and President Member of Competitive Markets Advisory Council, Chairman of Executive Committee and Member of Strategic Steering Committee
Edward Gogol, Managing Solutions
Michael Spencer, Director
John Peschier, Managing Relations
Jason Weller, Managing Strategy
Martin Gepsman, Independent Director
William Hobert, Independent Trustee
Christopher Bowen, Chief MD
Elizabeth Gisch, Managing Management
Sean Tully, Senior Managing Director - Interest Rates, OTC Products
Eileen Keeve, Managing Devel
William Shepard, Independent Director
Kevin Lennon, Managing Estate

CME Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CME a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

CME Investors Sentiment

The influence of CME's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in CME. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to CME's public news can be used to forecast risks associated with an investment in CME. The trend in average sentiment can be used to explain how an investor holding CME can time the market purely based on public headlines and social activities around CME Group. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
CME's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for CME's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average CME's news discussions. The higher the estimated score, the more favorable is the investor's outlook on CME.

CME Implied Volatility

    
  23.16  
CME's implied volatility exposes the market's sentiment of CME Group stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if CME's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that CME stock will not fluctuate a lot when CME's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CME in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CME's short interest history, or implied volatility extrapolated from CME options trading.

Pair Trading with CME

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CME position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CME will appreciate offsetting losses from the drop in the long position's value.

Moving together with CME Stock

  0.81MORN MorningstarPairCorr

Moving against CME Stock

  0.67DHIL Diamond Hill InvestmentPairCorr
  0.63MCBC Macatawa Bank Fiscal Quarter End 31st of March 2024 PairCorr
  0.61MBCN Middlefield Banc Fiscal Quarter End 31st of March 2024 PairCorr
  0.56VALU Value LinePairCorr
  0.51SPGI SP Global Financial Report 25th of April 2024 PairCorr
The ability to find closely correlated positions to CME could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CME when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CME - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CME Group to buy it.
The correlation of CME is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CME moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CME Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CME can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether CME Group is a strong investment it is important to analyze CME's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CME's future performance. For an informed investment choice regarding CME Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for CME Stock analysis

When running CME's price analysis, check to measure CME's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CME is operating at the current time. Most of CME's value examination focuses on studying past and present price action to predict the probability of CME's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CME's price. Additionally, you may evaluate how the addition of CME to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Correlations
Find global opportunities by holding instruments from different markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Is CME's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CME. If investors know CME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CME listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.276
Dividend Share
4.4
Earnings Share
8.86
Revenue Per Share
15.512
Quarterly Revenue Growth
0.192
The market value of CME Group is measured differently than its book value, which is the value of CME that is recorded on the company's balance sheet. Investors also form their own opinion of CME's value that differs from its market value or its book value, called intrinsic value, which is CME's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CME's market value can be influenced by many factors that don't directly affect CME's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CME's value and its price as these two are different measures arrived at by different means. Investors typically determine if CME is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CME's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.